Activity loss is associated with cognitive decline in age-related macular degeneration. by Rovner, Barry W et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Psychiatry and Human Behavior
Faculty Papers Department of Psychiatry and Human Behavior
Winter 1-1-2009
Activity loss is associated with cognitive decline in
age-related macular degeneration.
Barry W. Rovner
Thomas Jefferson University, barry.rovner@jefferson.edu
Robin J. Casten
Thomas Jefferson University
Benjamin E. Leiby
Thomas Jefferson University
William S. Tasman
Thomas Jefferson University
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/phbfp
Part of the Medicine and Health Commons, and the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Psychiatry and Human Behavior Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Rovner, Barry W.; Casten, Robin J.; Leiby, Benjamin E.; and Tasman, William S., "Activity loss is
associated with cognitive decline in age-related macular degeneration." (2009). Department of
Psychiatry and Human Behavior Faculty Papers. Paper 5.
http://jdc.jefferson.edu/phbfp/5
 1
As submitted to: Alzheimer’s and Dementia and later 
published as: “Activity Loss is Associated with 
Cognitive Decline in Age-Related Macular Degeneration.” 
Alzheimer’s and Dementia. Volume 5, Issue 1, January 
2009, Pages 12-17  
 
DOI: 10.1016/j.jalz.2008.06.001 
 
Perspectives 
 
Activity Loss is Associated with Cognitive Decline in Age-
Related Macular Degeneration 
 
 
 
Barry W. Rovner, MD 
Departments of Psychiatry and Neurology 
Jefferson Medical College 
Philadelphia, Pa 
 
Robin J. Casten, PhD 
Department of Psychiatry and Human Behavior 
Jefferson Medical College 
 
Benjamin E. Leiby, PhD 
Division of Biostatistics 
Department of Pharmacology and Experimental Therapeutics 
Jefferson Medical College 
     
William S. Tasman, MD 
Wills Eye Institute 
Department of Ophthalmology 
Jefferson Medical College 
 
 
 
 
Address for correspondence and reprints:    
Barry W. Rovner, MD 
Jefferson Hospital for Neuroscience 
900 Walnut Street, 4th Floor 
Philadelphia, PA  19107 
barry.rovner@jefferson.edu 
 
 
 
 2
 
 
 
 
 
 
 
 
 
ABSTRACT:  
 
Objective: To determine whether relinquishing cognitive, 
physical, and social activities is associated with an increased 
risk of cognitive decline in patients with age-related macular 
degeneration (AMD). 
 
Design:  Three year longitudinal study of 206 nondemented 
patients with AMD. 
 
Results: Twenty three subjects (14.4%) declined cognitively.  
Age, sex, education, decline in visual acuity, and number of 
dropped activities were associated with cognitive decline; each 
additional dropped activity increased the risk by 58%. Subjects 
who relinquished 3 activities were 3.87 times [95% CI 1.95, 
7.76] more likely to become demented than subjects who 
relinquished no activities; those who relinquished 5 activities 
were 9.54 times [95% CI 3.05, 30.43] more likely. A multivariate 
model demonstrated that number of dropped activities was a 
powerful predictor of cognitive decline after controlling for 
relevant risk factors, particularly for subjects less than 80 
years of age.    
 
Conclusion:  Relinquishing valued activities is associated with 
an increased risk of cognitive decline in older patients with 
vision loss due to AMD.  These data suggest the importance of 
promoting optimal cognitive and physical health in patients with 
AMD and perhaps other chronic diseases.   
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Introduction: 
 
Recent studies suggest that complex mental activity, physical 
exercise, and social engagement may prevent cognitive decline in 
older persons.1-9  It is uncertain, however, whether medical 
conditions that decrease participation in these activities are 
associated with cognitive decline.  We investigated that 
possibility in older persons with age-related macular 
degeneration (AMD). AMD is a highly disabling degenerative 
disease of the macular region of the retina that leads to 
geographic atrophy (one type of dry AMD) or choroidal 
neovascularization (wet AMD).10 It is the leading cause of legal 
blindness in older persons in the United States, affects more 
than 10 million people, and prevents many from reading, driving, 
socializing and pursuing hobbies.11-14 
 
Some researchers have noted intriguing relationships between AMD 
and Alzheimer’s disease (AD).15  In both conditions, misfolded 
amyloid beta peptides accumulate (in the retina and in the 
brain, respectively) and may play a central role in their 
onset.16  If this is the case, cognitive and vision impairment in 
AMD may reflect a shared pathogenesis.  Alternatively, vision 
loss may lead to cognitive decline via deafferentation of the 
visual system from the sensory cortex.17  Vision loss may also 
result in behavioral changes (e.g., relinquishing valued 
activities like reading and socializing) that indirectly and 
adversely affect neural function and can lead to or unmask 
incipient cognitive decline.6   
 
In this study, we examined whether relinquishing cognitive, 
physical, and/or social activities is associated with an 
increased risk of cognitive decline, using data from the 
Preventing Depression in AMD Trial.18 This was a 12 month 
randomized controlled clinical trial comparing the efficacy of 
problem-solving treatment (PST) versus usual care to prevent 
depressive disorders in older patients with AMD. At the baseline 
visit of the clinical trial, we assessed the extent to which the 
206 enrolled subjects had relinquished specific activities that 
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other research suggests prevent cognitive decline. Then, 3 years 
later, we interviewed the 160 available knowledgeable informants 
of subjects who were originally enrolled in the clinical trial 
to ascertain whether subjects had declined cognitively.  We 
tested the hypothesis that relinquishing more valued activities 
was associated with an increased risk for cognitive decline.   
 
 
 
Background: 
 
We recruited 206 subjects from December 2001 to July 2005 from 
the retinovitreous clinics associated with Wills Eye Institute 
in Philadelphia, PA, enrolling those with newly diagnosed 
neovascular AMD (NV-AMD) in one eye (within the preceding 6 
months) and pre-existing AMD in the fellow eye. The other 
inclusion criteria were age over 64 years and visual acuity in 
the better eye of 20/70 or worse.  We chose these parameters to 
identify older patients with recent bilateral visual impairment 
who were at high risk for vision-related disability.  The 
exclusion criteria were the presence of DSM-IV (Diagnostic and 
Statistical Manual of Mental Disorders) diagnoses of depressive 
or other axis I disorders, current treatment for depression, 
cognitive impairment, and confounding eye conditions. All 
subjects signed an informed consent form approved by Thomas 
Jefferson University’s Institutional Review Board. 
 
We reviewed fluorescein angiogram reports, confirmed clinical 
diagnoses with treating ophthalmologists, and sent introductory 
letters to 602 potentially eligible patients. Of these, 230 
(38%) were eligible (based on telephone screening) and were 
enrolled in the clinical trial.  The major reasons for 
nonparticipation were:  refusal (242; 40%); inability to contact 
(66; 11%); cognitive impairment (18; 3%); depression on 
screening (8; 1%) and other (38; 6%).  Subjects who did not 
participate did not differ from participating subjects on 
demographic characteristics, visual acuity nor a screening 
measure of depression (data not shown).   
 
We screened for cognitive impairment at baseline for the 
clinical trial using an abbreviated version of the Mini-Mental 
Status Examination that omits vision-dependent items.19 This 
version included orientation to time (i.e., day, month, and 
year), spelling “world” backwards, and delayed recall of 3 
words. Possible scores ranged from 0 to 11 with higher scores 
indicating better cognitive function. To be eligible, subjects 
needed to answer the 3 orientation questions correctly, score at 
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least 3 of 5 on “world” backwards, and recall 2 of 3 words on 
delayed recall.  We repeated this version of the Mini-Mental one 
year later at the end of the clinical trial. 
 
At baseline, we asked subjects to rate their participation in 
(including whether they had relinquished any) complex cognitive 
activities, physical exercise, and social engagement using the 
corresponding items of the National Eye Institute Vision 
Function Questionnaire (NEI VFQ-17).20  We targeted the following 
6 activities: reading, exercise/sports, hobbies, spectator 
activities, social activities, and cards/games. Each was scored 
categorically as to whether the subject continued to engage in 
(scored 0) or had relinquished the activity (scored 1). Scores 
were summed (range 0 to 6) with higher scores indicating a 
greater number of relinquished activities. 
 
Following the baseline assessment, 206 of the 230 (90%) subjects 
were randomized to the PST and control groups in a 1:1 
allocation ratio. Twenty four subjects were not randomized 
because of consent withdrawal (N=19), depression (N=4) or 
cognitive impairment (N=1) on further screening. From January 
2002 to August 2005, PST-trained therapists administered six 
weekly 30-45 minute PST sessions over 8 weeks to PST-assigned 
subjects. PST is a manual-driven psychological treatment that 
teaches problem-solving skills to define problems, establish 
realistic goals, generate and implement solutions, and evaluate 
outcomes.27 Subjects in the control condition received usual care 
from their ophthalmologists and other health care providers.  
 
Assessments during the Clinical Trial: Research nurses with 
extensive training in ophthalmology and psychiatry obtained 
informed consent and conducted clinical examinations in 
subjects’ homes. Demographic characteristics included age, race, 
sex, years of education, and marital status.  We assessed best-
corrected distance visual acuity in each eye separately using 
the Lighthouse Ferris-Bailey ETDRS Chart at baseline and month 
12.21 Scores were converted to the logarithm of the minimum angle 
of resolution (logMAR) with higher scores indicating greater 
impairment.22 Medical comorbidity was assessed using the Chronic 
Disease Score, which is derived from a weighted sum of 
medications taken for chronic illness, at baseline and month 
12.23 The score predicts health care utilization, costs, 
hospitalization rates and mortality with higher scores indicating 
greater medical disease burden.24  We created a vascular 
conditions variable at baseline (i.e., hypertension, diabetes, 
and stroke) to examine as a possible risk factor for cognitive 
decline. Incident DSM-IV defined-depressive disorders were 
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identified at months 2, 6, and 12 using the Modified Schedule 
for Affective Disorders and Schizophrenia and the Structured 
Interview Guide for the Hamilton Rating Scale.25,26   
 
Follow-up Informant Interviews after Completion of the Clinical 
Trial: From May to September 2006, we administered the Informant 
Questionnaire for Cognitive Decline in the Elderly (IQCODE) on 
one occasion by telephone to each of the 160 knowledgeable 
informants who were available for follow-up.28 The 160 subjects 
(76.6% of the 206 subjects enrolled in the clinical trial) on 
whom informants provided IQCODE scores did not differ in their 
demographic or clinical characteristics (including number of 
dropped activities, abbreviated MMSE scores at baseline, and 
incidence rates of depressive disorder during the trial) from 
the 46 subjects for whom IQCODE scores were unavailable (data 
not shown). The average length of time (and standard deviation) 
from subjects’ baseline evaluation to the IQCODE administration 
was 3.00 (.93) years.  The standard deviation reflects the 
relatively longer time to enroll the sample (i.e., 3.5 years) in 
relation to the 4 month time period during which informants were 
interviewed.   
 
The IQCODE measures cognitive decline from a premorbid level 
using informant reports (e.g. decline in recalling recent 
conversations, knowing the day and month).28 A 16-item short form 
of the original 26-item version correlates 0.98 with the full 
length version and has equally strong discriminatory power and 
internal consistency (alpha 0.93).29 Each of the 16 items is 
scored on a 5-point scale from 1-“better than before” to 5-“much 
worse” (3=no change).  Ratings are averaged to give an overall 
score from 1 to 5.  Factor analyses show that the IQCODE 
measures a single general factor of cognitive decline.28  A 
number of studies have demonstrated its reliability and validity 
against measures of cognitive change over time, clinical 
diagnoses, neuropathology and neuroimaging results.28  Jorm et al 
(2004) cited a variety of cut scores in different populations 
that maximize sensitivity and specificity: in community 
populations, cut-scores range from 3.3-3.6 and in patient 
samples from 3.4-4.0.28  None of the samples studied, however, 
closely resemble the visually impaired older adults that we 
studied.  For this reason, we took a conservative, empirical 
approach to define an appropriate cut-score that maximized 
specificity (to avoid false positives). We defined subjects as 
“cognitively impaired” if their IQCODE scores exceeded one 
standard deviation above the mean for this population.  A cut-
score of 3.81 met this criterion. 
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Statistical Methods:  Due to the variability in follow-up time, 
the measure of interest in describing cognitive decline is the 
incidence density, which is the number of new cases divided by 
the total person years of follow-up.  Poisson regression was 
used to model the incidence of cognitive decline while adjusting 
for different amounts of follow-up time.  Generalized Estimating 
Equation (GEE) methods were used to adjust standard errors and 
p-values.30 Clinically relevant variables were considered 
independent predictors of cognitive decline if they had a p 
value of 0.10 or less at the bivariate level.  A variable was 
considered a confounder of the association between dropped 
activities and cognitive decline if coefficients of terms in the 
model change by more than 15%.  A variable was called an effect 
modifier if the p-value for the interaction term was less than 
0.05.  
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Results:  The mean age and education (+/- standard deviation) of 
the sample was 81.1 (5.8) and 12.5 (3.1) years, respectively; 
70% were women; 98.1% were white; and 41.5% lived alone. The 
distribution of IQCODE scores was skewed to the right and had 
the following characteristics: range 2.63-5.00; median 3.13; and 
mean 3.30 (0.51). 
 
Twenty three subjects (14.4% of the sample) met the criterion 
for cognitive decline, representing an incidence density of 48.6 
cases per 1000 person years at risk.  Table 1 presents 
descriptive statistics for the sample and the bivariate 
relationships between the study measures and dementia status at 
follow-up.  The relationships are reported as incidence density 
ratios, which are based on Poisson regressions with number of 
years from the one-year assessment to follow-up as an offset 
variable.  The Table shows that age, sex, education, change in 
visual acuity, and number of dropped activities were associated 
with dementia at follow-up:  each 5 year increment in age 
increased dementia risk by 57%; each 4 year increment of 
education increased the risk by 36%; and each additional dropped 
activity increased the risk by 57%. Thus, subjects who 
relinquished 3 activities, for example, were 3.87 times [95% CI 
1.95, 7.76] more likely to become demented than subjects who 
relinquished no activities.  The risk for subjects who 
relinquished 5 activities increased to 9.54 times [95% CI 3.05, 
30.43]. 
 
Baseline abbreviated MMSE score, visual acuity in the better 
eye, medical comorbidity (i.e., Chronic Disease Score), vascular 
risk factors, and treatment assignment (PST vs. Usual Care) were 
unrelated to dementia risk. During the one year clinical trial, 
decline by more than one point on the abbreviated MMSE, incident 
depressive disorder, and changes in medical comorbidity were 
also unrelated to dementia risk. There was no significant 
correlation between number of dropped activities and baseline 
abbreviated MMSE (r =.05; p = .525) or change in MMSE scores 
from baseline to 12 months (r = 0.10; p = .213).   
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Table 2 shows the results of a multivariate model that included 
age, number of dropped activities, and their interaction. 
Although education, sex, and change in visual acuity were 
significant at the bivariate level, when added to the model they 
did not meet the criterion for confounding and were thus not 
included in the final model.  The interaction term of age X 
dropped activities was significant (p=0.013), indicating effect 
modification by age.  For those over age 80, each additional 
dropped activity increased the risk of cognitive decline by 27% 
(IDR=1.27; 95% CI [0.99, 1.63]; p=0.065).  For those under 80, 
the effect was stronger; each additional activity dropped 
increased the risk of cognitive decline by nearly 200% 
(IDR=2.96; 95% CI [1.59, 5.52]; p ≤ 0.001).   
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Discussion: We found that relinquishing valued activities was 
associated with an increased risk of cognitive decline in 
patients with recent bilateral vision loss due to AMD.  The 
effect was particularly strong in subjects under 80 years of 
age, consistent with other studies that have reported a more 
aggressive trajectory of decline in younger persons.31-32 .   
These findings are best understood, however, in the context of 
the study’s limitations. For one, the subjects we studied were 
not representative of most patients with AMD or the general 
population of older persons; thus, the results may have limited 
generalizability.  Second, we conducted no formal clinical or 
neuropsychological assessments at baseline to accurately 
characterize the cognitive function of the sample. At follow-up, 
we had no clinical validation of dementia diagnoses or precise 
knowledge of the temporal relationship between cognitive decline 
and loss of activities. The abbreviated MMSE that we used was 
likely insensitive to mild cognitive impairment and may have 
misclassified subjects at baseline or was insensitive to change 
over time. Other researchers, however, have used similar MMSE 
versions and have found equivalent power to distinguish demented 
from nondemented individuals. Regarding the IQCODE, although the 
validity of the cut score that we used is uncertain, it was more 
stringent than is commonly employed.  However, we excluded 
patients from the study who had a history or objective evidence 
of cognitive impairment and found no correlation between 
activity loss and cognitive measures at baseline or with 
cognitive change over one year. The latter suggests that a 
dementing process was not evident at the time of enrollment. 
Moreover, the incidence rate of cognitive decline that we 
observed is comparable to that reported in similar age cohorts 
(ranging from 32.6 to 59.9 cases per 1,000 patient years), which 
supports the validity of our findings.33   Nevertheless, we 
cannot exclude the possibility that activity loss may well have 
represented an early sign of dementia in some subjects.   
 
Alternatively, activity loss may have triggered or hastened the 
onset of cognitive decline although the association that we 
found between activity loss and cognitive decline does not 
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demonstrate this possibility.  Epidemiological and clinical 
studies have established a link between vision loss and 
cognitive decline, however.  Crews and Campbell (2004) examined 
the 1994 Second Supplement on Aging involving 9,447 older 
persons and found that those with self-reported vision loss were 
2.2 times more likely to be cognitively impaired than those 
without vision loss.34  Reyes-Ortiz et al (2005), using the 
population-based Hispanic Established Populations for 
Epidemiologic Studies of the Elderly, found that objective 
measures of vision impairment were associated with cognitive 
decline.35   In patients with AMD, the Age-Related Eye Disease 
Study Research Group (2006) found that increased macular 
abnormalities and reduced vision were associated with lower 
cognitive function and that persons with vision acuity worse 
than 20/40 in both eyes were more likely to be cognitively 
impaired than persons with better visual acuity.36    
 
The mechanisms linking vision loss, due to AMD in particular, 
with cognitive decline are uncertain although existing research 
suggests a number of possibilities.  AMD and Alzheimer’s disease 
(AD), for example, share histopathological features that suggest 
a common pathogenesis.  Amyloid beta deposition and inflammatory 
proteins characterize both ocular drusen and the neuritic 
plaques of AD.15  Some studies show that amyloid beta increases 
vascular endothelial growth factor (VEGF) and may lead to 
retinal pigment epithelium atrophy.16  In AD, amyloid beta-
induced neurotoxicity appears to be central to 
neurodegeneration.35  Moreover, previous studies have observed 
degeneration of the optic nerve and retina in Alzheimer’s 
disease.37   AMD and AD also share vascular risk factors (e.g. 
atherosclerosis) but have different genetic risks (i.e., the APO 
Є4 allele increases the risk for AD but decreases the risk for 
AMD).38,39 
 
In AD, we know that cognitive activities such as reading or 
playing board games or musical instruments have the potential to 
reduce the risk of dementia as do physical and social 
activities.1-4,7   The mechanism by which these activities 
maintain cognition is uncertain but may involve enhancing the 
brain’s capacity to tolerate neuropathology (i.e., increased 
neural reserve) via beneficial effects upon neuroplasticity, 
neurogenesis, or cortisol regulation.40,41   Although other 
mechanisms are possible, our finding that activity loss is 
associated with cognitive decline in AMD suggests the importance 
of maintaining activities in the face of vision loss.  This 
finding may also apply to patients with other chronic diseases 
that lead to the loss of or restrict participation in valued 
 12
activities. If so, promoting optimal cognitive and physical 
health may have wide relevance to the care of the growing 
population of older adults with chronic disabilities. 
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